Amazon to Introduce Air Delivery Service in Arizona via Drone 
Lotte Department Store Launches AI Translation Service for Foreign Customers 
Coca-Cola, Microsoft Forge $1.1B Alliance for Cloud and AI Innovation 
China Secures Banned Nvidia Chips Amid US Export Restrictions, Tenders Reveal 
PUMA Launches Innovative Compostable Sneaker RE:SUEDE 2.0 
How corporate involvement in psychedelic research could threaten public safety 
Rivian's Earth Day Special: $5,000 Off for Trading Gas Cars for Electric 
The language of insolvency: why getting it wrong can harm struggling firms 
Tesla Wipes Out New Content Marketing Unit, Fired All Team Members 
Adidas Unveils Groundbreaking Wheelchair Basketball Uniforms in Collaboration with Adaptive Sports Northwest 
Tesla Expands in Thailand: New Interest Rate Program and Land Acquisition Talks 
US Supreme Court Signals Support for Starbucks in Landmark Labor Law Case 
BMW Inaugurates Facility in South Korea for EV Technology Research and Development 
ADM’s Suspended CFO to Resign After Accounting Probe 
Hollys Brews Expansion with First Overseas Outlet in Japan in May 
Tevfik Arif shares his take on the post-COVID-19 real estate market in New York City 
7-Eleven Reveals Global Growth Plan to Boost Its F&B Programs 
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc. securities (NASDAQ:STML): (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Stemline investors under the federal securities laws.
To join the Stemline class action, go to http://www.rosenlegal.com/cases-1048.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and (2) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1048.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
